Source: Pharmacy Times articles
Hope Rugo, MD, discusses a multi-institutional real-world analysis showing that rechallenging trastuzumab deruxtecan after grade 1 interstitial lung disease (ILD) is generally safe and effective.
Read More
by MM360 Staff | May 29, 2025 | Myeloma News | 0 comments
Source: Pharmacy Times articles
Hope Rugo, MD, discusses a multi-institutional real-world analysis showing that rechallenging trastuzumab deruxtecan after grade 1 interstitial lung disease (ILD) is generally safe and effective.
Read More